Stocktoria
Editas Medicine, Inc. EDIT
Editas Medicine, Inc. (EDIT) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $40.5M at a -395.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| EDIT | Editas Medicine, Inc. | 1/9 | — | — | +25.4% |
| VYGR | Voyager Therapeutics, Inc. | 1/9 | -1.03 | — | -49.5% |
| SGMO | SANGAMO THERAPEUTICS, INC | 2/9 | — | — | -31.6% |
| KYMR | Kymera Therapeutics, Inc. | 3/9 | 9.79 | — | -16.7% |
| CHRS | Coherus Oncology, Inc. | 4/9 | — | 1.4 | +59.8% |
| FENC | FENNEC PHARMACEUTICALS INC. | — | -4.88 | — | -6.1% |
| CCCC | C4 Therapeutics, Inc. | 3/9 | -2.12 | — | +1% |
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
FAQ
Is EDIT financially healthy?
Editas Medicine, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does EDIT pay a dividend?
No, Editas Medicine, Inc. does not currently pay a dividend.
How profitable is EDIT?
In FY2025, Editas Medicine, Inc. had a net margin of -395.0% and a return on equity of -586.6%.
What is the analyst price target for EDIT?
The average Wall-Street price target for Editas Medicine, Inc. is $5.78, about 103.4% above the recent price, from 9 analysts.
Is EDIT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Editas Medicine, Inc.: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.